AGTX-2004 is a CB1R antagonist that has produced compelling pre-clinical
data in its ability to lower blood glucose, body weight and triglycerides and
thus its promise as a potential treatment for T2D, obesity and NALFD.

AGTX-2004 Results in db/db Mice

“SD” stands for “Standard Diet”; “HFD” stands for “High Fat Diet”

These results demonstrate that AGTX-2004 was able to lower blood glucose while maintaining increased insulin levels. Importantly, AGTX 2004 was able to maintain sensitivity to insulin, hence demonstrating potential efficacy inT2D patients.

Data courtesy NHRI Taiwan

AGTX-2004 Results in DIO Mice Compared to Rimonabant

In Diet Induced Obese (DIO) mice, AGTX-2004 was able to demonstate superiority over both control and rimonabant to lower body weight and hepatic lipids, thus demonstrating is potential efficacy in patients with obesity and NAFLD.

Daily oral dosing AGTX-2004 (PO, vehicle: DMSO/Tween80/water,1/1/8)
R = Rimonabant; STD = BALB Mouse; DIO = Diet Induce Obese Mouse
Data courtesy NHRI Taiwan


AGTX-2003 is a CB1R inverse agonist that has demonstrated an ability to reverse liver
steatosis and lower key markers responsible for the production of hepatic lipids.

AGTX-2003 Results in DIO Mice

As per panel A, AGTX-2003 at 1mg/kg was able to reverse liver steatosis, and these results were further reinforced by the levels of liver enzymes (AST and ALT) and hepatic lipids (LDH), which are associated with NAFLD and NASH.

Maitra, R. et al, ACS Pharmacol. Transl. Sci. 2021, 4, 757−764

AGTX-2003 Gene Expression Analysis

The administration of AGTX-2003 led to down regulation of key genes implicated in NALFD and NASH such as PPAR gamma and alfa, as well as Srebf1 and Srebf2.

Maitra, R. et al, ACS Pharmacol. Transl. Sci. 2021, 4, 757−764

AGTX-2004 and AGTX-2003 Have Unique Positioning in the Areas of Metabolic Diseases